CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering

Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the expansion of MOx, the Company’s multiomic diagnostic portfolio, now incorporating cutting-edge transcriptomic analysis.

CENTOGENE’s MOx 2.0 is a single-step multiomic solution that combines DNA sequencing, biochemical testing, and now RNA sequencing to provide physicians with the most comprehensive testing capability.

Transcriptomics examines the transcripts to reveal mutation-specific RNA patterns, differences in gene expression, and how cells and tissues respond to environmental or physiological changes. Using RNA sequencing, a more complete picture of disease biology and response to drugs can be established.

“Rare and neurodegenerative diseases often present complex diagnostic challenges, requiring a deeper understanding of the genetic and molecular factors at play,” said Prof. Peter Bauer, Chief Medical & Genomic Officer at CENTOGENE. “We understand that genomics alone is not enough, so we have developed what we believe to be one of the most comprehensive and innovative multiomic offerings on the market that helps patients receive an accurate diagnosis. Leveraging transcriptomics, the CENTOGENE Biodatabank, and CentoCard, MOx 2.0 enables us to translate variants of unknown significance into a precise diagnosis and revolutionize precision medicine for rare and neurodegenerative disease patients.”

MOx 2.0 – A Paradigm Shift in Real-World Patient Diagnostics

CENTOGENE’s enhanced multiomic portfolio consists of three seamlessly integrated key updates:

Highest Diagnostic Yield With Transcriptomics

• By integrating RNA sequencing, a more complete picture of disease biology can be established, capturing over an estimated 60% of tested patients with suspected genetic disorders, compared to 40-50% with standard Whole Exome and Genome Sequencing
  
  

Simplified Logistics

• Leveraging CentoCard, CENTOGENE’s state-of-the-art filter card technology for extracting high-quality extraction of DNA, RNA, enzymes, and metabolites from dried blood spots, sample collection and shipping has been streamlined – ensuring accessible multiomic testing for patients worldwide